Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

<div>Longitudinal analysis of serum suPAR level between survivors and nonsurvivors in HB-ACLF patients during a 4-week therapy. (a) Temporal dynamics of serum suPAR level in HB-ACLF patients between the survivors and nonsurvivors group. (b) Comparison of suPAR level at individual time between the survivors and nonsurvivors group.</div>

Gastroenterology Research and Practice

fig3

Figure 3

Figure 3: Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure 

Figure 3 | Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure 